Global scleroderma therapeutics market is projected to grow at a steady CAGR of 5.2% in the forecast period of 2019 to 2026. The years considered for study are as mentioned below.
The scleroderma is a rare disease in which it affects the body by hardening connective tissue. This happens due to excessive production of collagen in body. Fewer than 500,000 people in the United States have scleroderma. The North America region is dominating the market because Americans and Native Americans generally have more severe scleroderma than Caucasians. The North America region is growing because number of companies are providing better treatment facilities to people and the government of North America is also have provided insurance coverage to their people. With such facilities the treatment is increasing in these regions which are ultimately helping the market to grow.
AstraZeneca dominated the global scleroderma therapeutics market. The other key players existing in the market includes Argentis Pharmaceuticals, LLC., Pfizer Inc, AbbVie Inc., Sanofi, ALLERGAN, viDA Therapeutics Inc., Active Biotech AB., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Johnson & Johnson Services, Inc., Daval International Limited and among others.
AstraZeneca headquartered in Cambridge, U.K. was founded in 1992. The company is involved in discovery, development, manufacturing and commercialization of biopharmaceutical products. It has Biopharmaceuticals as its business segment. The main focus of the company is on the areas such as cardiovascular, renal and metabolism, oncology, respiratory, inflammation and autoimmunity, infection and vaccines, neuroscience, all medicines and others. It has 64,600 employees as of December 2018.
It has geographical presence in Middle East & Africa, Europe, North America, South America and Asia-Pacific. It operates through its subsidiaries such as MedImmune, LLC (U.S.), AstraZeneca Pharma India Limited (India), AstraZeneca AB (Sweden), Pearl Therapeutics Inc. (U.S.), AstraZeneca Pharmaceuticals LP (U.S.) and others.
F. Hoffmann-La Roche Ltd:
F. Hoffmann-La Roche Ltd headquartered in Rotkreuz, Switzerland was founded in 1896. The company focuses on the development, sales and manufacture pharmaceuticals and diagnostics. The company has two operating divisions’ pharmaceuticals and diagnostics. In pharmaceutical segment, company is involved in R&D and manufacturing medicines in oncology, inflammation/immunology, neuroscience, infectious diseases, ophthalmology, others. In diagnostic segment, company involved their business in centralised and point of care solutions, molecular diagnostics, tissue diagnostics and diabetes care. F. Hoffmann-La Roche Ltd has drugs in clinical trials like Placebo and Tocilizumab, which are available in phase 3 of clinical trial to treat the systemic sclerosis. In this clinical trial study the efficacy and safety of tocilizumab is compared with placebo for Systemic Sclerosis. This product can be a blockbuster for the forecasted years.
The company has its presence all over the world. The company has various subsidiaries such as Roche NimbleGen, Inc. (U.S.), Roche Oy (Finland), Hoffmann-La Roche Inc. (U.S.), Roche Holding AG (Switzerland), Roche SAS (France) and many others.
Novartis AG headquartered in Basel, Switzerland was founded in 1996. The company is engaged in research, development, manufacturing and marketing of healthcare products. The company’s business segments are Innovative Medicines, Sandoz, and Alcon. The Innovative Medicines business division is engaged in R&D and manufacturing of patented prescription medicines. Sandoz division manufactures prescription medicines and pharmaceutical active ingredients and intermediates. Alcon division is engaged in R&D, manufacturing and marketing of eye care products. Our Market Focused Segment is Innovative Medicines.
The drugs STI571 (Gleevec (imatinib)) is in clinical trial in phase 2 for Systemic Sclerosis, Scleroderma and it can be used by Male and female patients who are around 18 years of age and having early diffuse systemic sclerosis (Disease duration < 18 months from the first non-Raynaud's symptom), Patients with a modified Rodnans Skin Score (MRSS) of at least 20 in the absence of trunk involvement or a MRSS of at least 16 in patients with trunk involvement can use these drugs.
It operates in geographic segments like Americas, Europe, Asia-Pacific, and Middle East & Africa. It operates through its subsidiaries such as Sandoz (Germany), Alcon (U.S.), AveXis (U.S.), Endocyte (Indiana), Hexal AG (Germany) and among others.
Global Scleroderma Therapeutics Market – Industry Trends and Forecast to 2026
Asia-Pacific Scleroderma Therapeutics Market – Industry Trends and Forecast to 2026
Europe Scleroderma Therapeutics Market – Industry Trends and Forecast to 2026
Middle East and Africa Scleroderma Therapeutics Market – Industry Trends and Forecast to 2026
North America Scleroderma Therapeutics Market – Industry Trends and Forecast to 2026